Featured Research

from universities, journals, and other organizations

Scientists Use Old Enemy To K.O. Cancer

Date:
August 13, 2008
Source:
University of Warwick
Summary:
Chemists are pulling cancer onto a sucker punch by getting infected cells to drop their guard -- according to research published today. They are using the metal ruthenium as a catalyst to a cancer-busting reaction which calls up an old cellular enemy -- oxidants -- as an ally.

Chemists are pulling cancer onto a sucker punch by getting infected cells to drop their guard – according to new research. They are using the metal ruthenium as a catalyst to a cancer-busting reaction which calls up an old cellular enemy – oxidants – as an ally.

Cancer adapts quickly to traditional drugs which attack infected cells directly. But the latest laboratory tests reveal a second line of defence using ruthenium as a catalyst to a reaction which stops cells developing the anti-oxidant chemical glutathione.

As the targeted cell is forced to drop its glutathione defences, the oxidant levels increase, and the cancerous cell dies.

University of Warwick Chemistry Professor Peter Sadler explained: "We know oxidants produce free radicals that damage cells. Our experiments show ruthenium produces a reaction in the cell which destroys its anti-oxidant defence glutathione – thus destroying the cancer-infected cell.

"Working with colleagues in Edinburgh University and Oncosense we've proved this could be an effective line of defence against cancer."

Scientists working on the project now hope to move the research out of the laboratory – the next stage for this work would be medical trials.

The research was funded the Biotechnology and Biological Sciences Research Council (BBSRC), and the findings are published in the Proceedings of the National Academy of Sciences - August 2008.


Story Source:

The above story is based on materials provided by University of Warwick. Note: Materials may be edited for content and length.


Cite This Page:

University of Warwick. "Scientists Use Old Enemy To K.O. Cancer." ScienceDaily. ScienceDaily, 13 August 2008. <www.sciencedaily.com/releases/2008/08/080812135650.htm>.
University of Warwick. (2008, August 13). Scientists Use Old Enemy To K.O. Cancer. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/08/080812135650.htm
University of Warwick. "Scientists Use Old Enemy To K.O. Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/08/080812135650.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins